###### Strengths and limitations of this study

-   Risk factors of non-alcoholic fatty liver disease (NAFLD) in central China.

-   Biomarkers of NAFLD using metabolomics.

-   Prediction ability of metabolic markers using receiver operating characteristic curve.

-   No information on education.

Introduction {#s1}
============

China has the world's largest population and is undergoing rapid economic growth and social reform. This advancement has paralleled demographic, lifestyle and cultural changes, which have exerted notable effects on the health profile of China's residents and placed significant constraints on the country's healthcare system.[@R1]

Such changes are apparent in major cities of central China, such as Wuhan. The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, now the most common chronic disease among Chinese adults in China, and the rates exceed those of equally important epidemics, including obesity, hypertension and type 2 diabetes. NAFLD is followed by an increase in overall cardiovascular morbidity and mortality.[@R2] It has been estimated that NAFLD will be the most frequent indicator for liver transplantation and regeneration in the coming decades.[@R5] Additionally, because population ageing and the continual increase in obesity and hypertension rates over the recent decades, the prevalence and impact of NAFLD in China are expected to increase. Accordingly, NAFLD is a major public health burden.

The reported prevalence of NAFLD among Chinese adults ranges from 15% to 30%.[@R5] NAFLD prevalence increases with age, most notably from the fourth decade of life onwards (40--60 years of age).[@R5] Because of endocrine function variations and fat redistribution, the prevalence and risk factors for NAFLD may vary across different ages and between male and female populations.[@R10] However, the association of age and sex with NAFLD in central China is still unclear. Furthermore, the association of hypertension, obesity, hyperlipidaemia, insulin resistance and diabetes with NAFLD has been widely evaluated in adult cohorts,[@R14] and these metabolic traits are well-accepted risk factors at present for NAFLD. Nonetheless, limited data are available on the association of NAFLD with other covariant traits.[@R17] Metabolomics provides integrated information on biological status and can investigate molecular variations with disease phenotyping[@R19]; several markers for NAFLD have been identified previously.[@R5] Sphingolipids (SLs) and branched fatty acid esters of hydroxy fatty acids (FAHFAs) have been reported to protect against autoimmune and allergic disorders and type 2 diabetes, respectively[@R21]; the effects of SLs and FAHFAs on NAFLD are largely unclear.

Our present study was aimed at investigating the prevalence of NAFLD, elucidating the association of NAFLD with age, sex, metabolic factors and markers of liver injury, and identifying novel metabolites associated with NAFLD risk, via clinical examination, anthropometric assessment and targeted metabolomics.

Methods {#s2}
=======

Study population {#s2a}
----------------

All participants provided written informed consent prior to enrolment. The Wuhan study is an observational cross-sectional study of participants recruited from the Wuhan municipality in central China. Participants were recruited from routine health check-ups to assess the utility of health check-ups in determining the prevalence of and risk factors for NAFLD. Each participant completed a comprehensive interview and clinical examination that involved the collection of fasting blood and urine samples, abdominal ultrasonography, and anthropometric assessment.

Interview {#s2b}
---------

The interview, followed by the clinical examination, was performed by a physician and was designed to obtain information on demographic characteristics, medical history and comorbid conditions. Participants aged over 18 and below 80 years were included if they were not currently being treated for cancer or infectious disease or had undergone surgery in the previous year, and if they had no history of cancer or an infectious disease.

Biochemistry {#s2c}
------------

Fasting blood and urine samples were collected on clinical examination. Blood alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), gamma-glutamyl transferase, glucose, total bilirubin, triglycerides and uric acid levels were measured using automatic enzymatic procedures (Nanjing Jiancheng Sci-tech, China). Hepatitis B surface antigen (HBsAg), triiodothyronine, thyroxine (T4) and thyroid-stimulating hormone were examined via automatic immunoassays (Roche Diagnostics, Mannheim, Germany).

Diagnosis of NAFLD {#s2d}
------------------

Abdominal ultrasonography was performed on all participants by accredited medical technicians using a Hitachi HI VISION 900 ultrasound machine. Images were evaluated by a senior pathologist. NAFLD was diagnosed by the technician according to ultrasonography.[@R23] Participants with any of the following possible secondary causes of fatty liver were excluded from the current analyses: (1) excessive alcohol intake,[@R26] (2) anti-hepatitis C virus (HCV) or positive HBsAg, or (3) use of drugs historically for treating fatty liver (ie, amiodarone, corticosteroids, methotrexate or tamoxifen).[@R13]

Metabolic covariates {#s2e}
--------------------

Anthropometric measurements were performed by accredited nurses. Body mass index (BMI) was defined as the measured weight (kg) divided by height squared (m^2^). Body fat ratio (BFR) was equal to fat weight (kg) divided by body weight (kg). The average of two resting blood pressure (BP) measurements at a single visit after a 10 min break was used for analysis.

Metabolic traits were defined as the following: obesity (BMI ≥28 kg/m^2^), hypertension (BP ≥140/90 mm Hg or antihypertensive drug treatment), BFR ≥25 for women or ≥20 for men, blood triglycerides ≥1.7 mmol/L, blood fasting glucose ≥6.1 mmol/L, liver enzyme elevation (AST ≥40 U/L or ALT ≥40 U/L), uric acid ≥357 μmol/L for women or ≥416 μmol/L for men, or impaired oleic acid-hydroxy oleic acid (OAHOA) (\<5 nmol/L).

Targeted Liquid Chromatography/Mass Spectrometry analysis of SLs and FAHFAs {#s2f}
---------------------------------------------------------------------------

To identify SLs,[@R21] silica column-affectionate lipid fractions were analysed by reverse-phase high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS)/MS (Agilent C18 column connected with Thermo Scientific LTQXL; gradients of water to methanol, 10:90 to 0:100) to identify spots present in both control and liver disease. Identified lipid species of interest were purified by reverse-phase HPLC (Varian Prostar/Agilent C18 column) and subjected to structural analysis.

FAHFAs were measured by HPLC-MS[@R22] (an Agilent 6410 Triple Quad liquid chromatography (LC)/mass spectrometry (MS) via multiple reaction monitoring (MRM) in a negative ionisation mode). Briefly, extracted and fractionated samples were dissolved in 25 mL MeOH; 10 mL was injected for further analysis. A Luna C18(2) (Phenomenex) column was used with an in-line filter (Phenomenex). Distinct FAHFAs were dissolved via isocratic flow (0.2 mL/min for 120 min, solvent: 93:7 MeOH:H~2~O, 5 mM ammonium acetate, 0.01% ammonium hydroxide). Transitions for OAHOAs were m/z 561.5 → m/z 281.2 (collision energy (CE)=30 V), and m/z 561.5 → m/z 279.2 (CE=25 V).

Statistical analyses {#s2g}
--------------------

Baseline characteristics were analysed using descriptive statistics. U tests, Χ^2^ tests or Wilcoxon rank-sum tests (for medians) and Student's t-tests (for means) were used to evaluate the significance of differences in the distribution of categorical data and continuous data, respectively. To examine the relations between traits and NAFLD, we performed binary or multiple logistic regression analyses. We calculated the area under the receiver operating curve to assess prediction ability of metabolic markers. A P value of \<0.05 was considered statistically significant unless stated otherwise. Data analyses were performed using SPSS V.17.0.

Results {#s3}
=======

Study population {#s3a}
----------------

In total, 1500 participants were enrolled. Twenty-one participants were excluded due to absence of clinical data. Thus, a total of 1479 study participants were included in the final analysis, of whom 447 reported their age and had no more than one disease, if any (denoted as the 'subset'). Patients' general characteristics are shown in [table 1](#T1){ref-type="table"}. Men accounted for 40% of the study population (38% of the subset). Participants' mean age was 44.3±11.9 (range 20--74) years.

###### 

Participant characteristics

  Indicators                     Total          NAFLD         No NAFLD       P value
  ------------------------------ -------------- ------------- -------------- ---------
  \(A\) Subset                                                               
   n                             447            102 (22.8%)   345 (77.2%)    
   Age (years)                   44.3±11.9      44.6±10.8     44.0±12.1      0.609
   Age range                     4.0±1.2        4.0±1.2       3.9±1.2        0.608
   Obesity                       235 (51.8%)    94            141            \<0.001
   Body fat                      309 (68.1%)    89            220            \<0.001
   Blood lipids                  87 (19.2%)     21            66             0.745
   Hypertension                  55 (12.1%)     23            32             0.003
   Male                          171 (38.3%)    64            107            \<0.001
   Elevated liver enzymes        18 (4.0%)      7             11             0.174
  \(B\) Total study population                                               
   n                             1479           365 (24.7%)   1114 (75.3%)   
   Obesity                       809 (54.7%)    334           475            \<0.001
   Body fat                      1003 (67.8%)   309           694            \<0.001
   Blood lipid                   458 (30.9%)    163           295            \<0.001
   High blood glucose            71 (4.8%)      43            28             \<0.001
   Hypertension                  314 (21.2%)    129           185            \<0.001
   Abnormal uric acid            83 (5.6%)      38            45             \<0.001
   Male                          590 (39.8%)    214           376            \<0.001
   Impaired liver function       32 (0.2%)      12            20             0.142
   Elevated liver enzymes        110 (0.7%)     53            57             \<0.001

Age ranges of 20--30, 30--40, 40--50, 50--60 and ≥60 are 2, 3, 4, 5 and 6.

Conditions were defined as follows: obesity (body mass index ≥24 kg/m^2^), hypertension (blood pressure ≥140/90 mm Hg or antihypertensive drug treatment), body fat ratio ≥25 for women or ≥20 for men, blood triglycerides ≥1.7 mmol/L, blood fasting glucose ≥5.6 mmol/L, impaired liver function (positive HBsAg), liver enzyme elevation (AST ≥40 U/L or ALT ≥40 U/L), and uric acid ≥357 µmol/L for women or ≥416 µmol/L for men.

Mean values are provided with SD, unless otherwise noted as n (%). Differences between participants with and without NAFLD were evaluated with t-tests or the Wilcoxon-Mann-Whitney test for continuous variables and the χ^2^ test for categorical variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; NAFLD, non-alcoholic fatty liver disease.

Prevalence of NAFLD {#s3b}
-------------------

The prevalence of NAFLD, as determined by ultrasound and biopsy, was 24.7% (22.8% in the subset).

The peak prevalence of NAFLD was 26.4% and 26.3% in this study between the ages of 30--40 years and 50--60 years, respectively ([table 2](#T2){ref-type="table"}).

###### 

NAFLD prevalence across age range

  Age range (years)   Participants, n   Participants with NAFLD, n   NAFLD prevalence,%   U test
  ------------------- ----------------- ---------------------------- -------------------- --------------
  20--30              64                10                           15.6                 1.22
  30--40              102               27                           26.4                 0.75
  40--50              120               26                           21.7                 0.18
  50--60              111               30                           27.0                 1.00
  ≥60                 50                9                            18.0                 0.64
  Total               447               102                          22.8                 1.64 (α=0.1)

NAFLD, non-alcoholic fatty liver disease.

The prevalence of NAFLD demonstrated an increasing trend with advancing age (OR 1.049, P=0.607), and after adjustment for sex and metabolic features NAFLD tended to be inversely correlated with age (OR 0.844, 95% CI 0.667 to 1.068; P=0.157). NAFLD was diagnosed in 37.4% of men and 13.8% of women (P=0.084). In multivariate analysis, after adjustment for metabolic features and age, male sex was associated with NAFLD (OR 3.484, 95% CI 2.028 to 5.988; P\<0.001; [table 3A](#T3){ref-type="table"}).

###### 

Multivariate adjusted models for liver disease subtypes

  Variables                  OR       P value
  -------------------------- -------- ---------
  (A) Subset                          
   Sex (male)                3.484    \<0.001
   Obesity                   11.738   \<0.001
   Body fat                  2.285    0.033
   Elevated liver enzyme     2.237    0.105
   Hypertension              1.865    0.089
  \(B\) Whole population              
   Sex (male)                2.646    \<0.001
   Obesity                   8.494    \<0.001
   Body fat                  1.833    0.001
   Blood lipid               1.340    0.046
   Blood glucose             3.324    \<0.001
   Impaired liver function   1.859    0.094
   Elevated liver enzyme     3.150    \<0.001
   Hypertension              1.451    0.017

Conditions were defined as follows: female sex=1, obesity (body mass index ≥28 kg/m^2^), hypertension (blood pressure ≥140/90 mm Hg or antihypertensive drug treatment), body fat ratio ≥25 for women or ≥20 for men, blood fasting glucose ≥6.1 mmol/L, and liver enzyme elevation (AST ≥40 U/L or ALT ≥40 U/L).

ORs and the corresponding P values derived from binary or multiple logistic regression analyses using SPSS V.17.0 software.

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Association between NAFLD and metabolic features {#s3c}
------------------------------------------------

Among metabolic covariates, obesity and hypertension occurred more frequently in participants with advancing age (OR 1.471 and 1.822, respectively; P\<0.001). Increased body fat was more prevalent in women than in men (OR 2.042, P\<0.001 (OR 1.754, P=0.007 in the subset)), and obesity (OR 0.537, P\<0.001), increased blood lipids (OR 0.829, P\<0.101) and hypertension (OR 0.769, P\<0.041) were more prevalent in men than in women (OR 0.472, P\<0.001; OR 0.902, P\<0.673; and OR 0.602, P\<0.080, respectively, in the subset).

In univariate analysis, all metabolic and anthropometric traits were significantly associated with NAFLD. In logistic regression analysis, after adjustment for sex, BMI ≥24 kg/m^2^ (OR 8.494, 95% CI 5.581 to 12.928; P\<0.001), BFR ≥25 for women and ≥20 for men (OR 1.833, 95% CI 1.286 to 2.756; P=0.001), triglycerides ≥1.7 mmol/L (OR 1.340, 95% CI 1.006 to 1.785; P=0.046), fasting glucose ≥6.1 mmol/L (OR 3.324, 95% CI 1.888 to 5.850; P\<0.001), BP ≥140/90 mm Hg or antihypertensive drug treatment (OR 1.451, 95% CI 1.069 to 1.970; P=0.017), uric acid ≥357 μmol/L for women and ≥416 μmol/L for men (OR 2.755, 95% CI 2.009 to 3.778; P\<0.001), and total OAHOA \<5 nmol/L (OR 1.340, 95% CI 1.006 to 1.785; P=0.046) (after adjustment for age ranges and sex in the subset, ORs for BMI, BFR and BP were 11.738 (95% CI 5.193 to 26.530, P\<0.001), 2.285 (95% CI 1.067 to 4.893, P=0.033) and 1.865 (95% CI 0.910 to 3.824, P=0.089), respectively) were independent predictors of NAFLD ([table 3A,B](#T3){ref-type="table"} and [table 4](#T4){ref-type="table"}). The prevalence of NAFLD demonstrated an increasing trend with lowering sphingosines (OR 1.448, P=0.156; [table 4](#T4){ref-type="table"}). Substitution of age ranges for continuous data (ie, absolute age) in logistic regression did not modify the relationships. When each metabolic trait was analysed independently, after adjustment for age and sex, ORs increased for obesity and hypertension with increasing age, and ORs increased for BFR with increasing age for patients aged \<50 years and decreased for patients aged ≥50 years. However, significant interactions were only observed between age and obesity (P\<0.001), and between age and hypertension (P\<0.001).

###### 

Metabolites associated with non-alcoholic fatty liver disease

  Metabolite    OR      P value   AUC     P value
  ------------- ------- --------- ------- ---------
  Uric acid     2.755   \<0.001   0.579   \<0.001
  Sphingosine   1.448   0.156     0.489   0.760
  OAHOA         1.340   0.046     0.612   0.001

Conditions were defined as sphingosine \<2 nmol/L and OAHOA (oleic acid-hydroxy oleic acid) \<5 nmol/L.

ORs, area under curve (AUC) and the corresponding P values derived from binary or multiple logistic regression, or receiver operating characteristic curve analyses using SPSS V.17.0 software.

Association between NAFLD and liver enzymes {#s3d}
-------------------------------------------

Participants with NAFLD had higher liver enzyme levels than participants without this condition (P\<0.001). Abnormal liver enzymes were also significantly associated with NAFLD, independent of sex (OR 3.150, P\<0.001). Normal liver enzyme levels, defined according to local guidelines (ALT \<40 U/L), were found in 85% of participants with NAFLD.

Discussion {#s4}
==========

Our results demonstrated that NAFLD was strongly associated with metabolic traits including higher body fat, obesity, hyperlipidaemia and impaired fasting glucose. We observed a higher prevalence of NAFLD in men than in women. We conformed the association of impaired uric acid and abnormal liver enzymes with NAFLD, and further identified impaired total OAHOA as a novel biomarker of NAFLD prevalence.

The average and peak prevalence of NAFLD in this study were 24.7% and more than 26%, respectively, close to the global prevalence of NAFLD, which was 25.24%, with the highest prevalence in the Middle East (31.79%) and South America (30.45%), and the lowest in Africa (13.48%).[@R27] The average and peak prevalence of NAFLD in Shanghai[@R5] were 20.82% and 28.44%, respectively, and those in Guangdong[@R6] were 17.2% and 27.4%, respectively. The former study was conducted from 2002 to 2003, and the latter in 2005. Our study, performed in 2010, revealed that the average prevalence is increasing, and the peak prevalence occurred at a younger age (30--40 years) than was reported by the previous studies in Shanghai (age of 60--69),[@R5] Guangdong (age of 60--69)[@R6] and worldwide (mean age of 70--79).[@R27] Thus, more attention should be given to the health of people in their 30s, when many marry and adopt lifestyle changes, especially in urban China. Unfortunately, we did not have access to information on participants' activity levels, and thus the effects of physical activity on NAFLD were not assessed. The reasons underlying the observed earlier peak prevalence require further investigation.

We observed that male sex was a risk factor for NAFLD. This finding differs from the results of the Guangdong study[@R6] and the Rotterdam study.[@R13] However, this finding is similar to that of the Shanghai study.

There are several possibilities for this discrepancy. First, the observed sex difference in NAFLD prevalence may be the result of body fat, which is a risk factor for NAFLD and was higher in men than in women in this study. Therefore, male sex may promote NAFLD through mediators such as increased body fat and hormonal change. Second, the sex difference in NAFLD may also result from a lower prevalence of boosted serum triglycerides, glucose and hypertension in women compared with men. A lower prevalence of boosted serum triglycerides, glucose and hypertension in women was reported in a previous study.[@R28] However, a causal relationship between NAFLD and these serum metabolic markers, as suggested by previous research,[@R29] could not be established in our research due to its cross-sectional characteristics. Third, abnormal liver enzymes were more prevalent in men than in women, and both were independent predictors of NAFLD.

We observed that the associations of the identified metabolites with NAFLD risk were pronounced in the Wuhan cohort. These metabolites might play a major role in the development of onset NAFLD. Uric acid was particularly associated with NAFLD in men with type 2 diabetes, besides insulin resistance and other metabolic factors.[@R31] High concentrations of uric acid induce the accumulation of reactive oxygen species in hepatocyte mitochondria, ultimately leading to mitochondrial damage,[@R32] and uric acid was positively correlated with other metabolic traits and was a risk factor for type 2 diabetes mellitus with NAFLD.[@R33]

Serum uric acid (SUA) is produced by purine nucleotide catabolism.[@R34] SUA subjects have an about twofold higher risk of NAFLD, as shown by ultrasonography. The risk may be independent of age, sex and obesity (indicated by BMI and waist circumference). SUA is an independent risk factor in NAFLD in both Uyghurs and Hans in north-western China.[@R35] Among participants with elevated SUA levels, women likely showed a greater risk of NAFLD than men.[@R36]

OAHOAs are present in humans, which are an endogenous branched FAHFAs, and levels are reduced with obesity and insulin resistance. OAHOA levels in serum are correlated highly with whole-body insulin sensitivity. OAHOAs are endogenous GPR120 ligands and may also exert anti-inflammatory effects in vivo through fatty acid-activated G-protein-coupled receptors (GPCRs), such as GPR120. Androgen-induced protein 1 (AIG1) and androgen-dependent TFPI-regulating protein (ADTRP), atypical integral membrane hydrolases, degrade bioactive FAHFAs,[@R37] and branched FAHFAs are preferred substrates of MODY8, a protein carboxyl ester lipase.[@R38] Changes in the concentrations of these anti-inflammatory metabolites and in their signalling networks may provide new targets for metabolic and inflammatory diseases.[@R22] GLUT4 expression and levels of FAHFAs with antidiabetic and anti-inflammatory effects regulate de novo lipogenesis in adipocytes.[@R39] Compared with healthy controls, FAHFAs are significantly decreased in the sera of patients with breast cancer.[@R40] Branched FAHFAs protect against colitis by controlling gut innate and adaptive immune responses.[@R41]

Our study also has some potential limitations. First, we cannot rule out the possibility of biased selection, since non-responders may have had different morbidities. Volunteers in research studies tend to be better educated, healthier and have better lifestyles.[@R42] Consequently, estimations of the prevalence of NAFLD may have been biased. Second, only 447 of the 1479 participants provided information on their ages, and we did not obtain data on participants' educational levels or incomes. Third, specific OAHOA isomers[@R22] require further study.

Conclusions {#s5}
===========

NAFLD is common in the study population. In this observational cross-sectional primary survey, we found that NAFLD was associated with male sex, and the peak prevalence occurred at a younger age. In particular, NAFLD was correlated with uric acid. Moreover, we identified OAHOA as a novel biomarker of NAFLD. Further studies are needed to explore the potential factors contributing to these relationships. However, this study is valuable in that it provides a reference on the prevention of NAFLD and related metabolic diseases with the rapid urbanisation, technological advancement and population ageing in China.
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